 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU, a company developing second-generation psychedelics for neuropsychiatric disorders, announced that former Food and Drug Administration FDA Psychiatry Division Director Thomas Laughren is joining the company as a regulatory advisor. Laughren led the Division of Psychiatry Products and the Center for Drug Evaluation and Research at the FDA. 